

The Gardasil-9® (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)) prescribing information and adverse event reporting are available at the end of this document.

Vaccines Confidence Chapters

The Vaccines Confidence Chapters are comprised of presentations and interactive workshops around 4 areas of vaccine confidence. The chapters aim to provide guidance to healthcare professionals and other relevant decision makers on **how to tackle common hurdles to HPV (Human Papillomavirus) vaccination**, as well as broader issues around vaccination.

Each presentation is approximately 45 minutes to 1 hour with a 30-minute workshop to follow, however these timings can be tailored to suit the availability of each immunisation team. The attendees who have consented to receive promotional information from MSD will also be emailed a **digital infographic summarising the key take home messages.**

Chapter one: An introduction to vaccination, HPV and vaccine hesitancy

- The importance of vaccines in maintaining public health
- The types of vaccination and how they work
- Components of a vaccine and how they contribute to its functionality
- The process of vaccines research and development
- HPV and cancer
- History and impact of the HPV National Immunisation Programme
- What is vaccine hesitancy, the impact on public health and the possible reasons for vaccine hesitancy

Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)) is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases³:





Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types

Genital warts (Condyloma acuminata) caused by specific HPV types

Chapter two: Building vaccine confidence

- Recent trends in vaccine hesitancy
- Factors affecting HPV vaccination in ethnic adolescent children
- HPV vaccination and boys
- The role of social media in vaccine hesitancy

Chapter three: Breaking down barriers to HPV vaccination

- Barriers to HPV vaccination and how these barriers are specific to different individuals
- Effective tools and strategies for overcoming barriers to HPV vaccination
- Case studies of tackling vaccine hesitancy

Chapter four: Practical tips on challenging misinformation

- The definition of misinformation and disinformation
- Misinformation around HPV vaccination
- Strategies for tackling misinformation
- HPV and cancer

Click here for training and resources around HPV vaccination on MSD Connect



The Gardasil-9® (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)) prescribing information and adverse event reporting are available at the end of this document.

ADVERSE EVENTS

Adverse events for any MSD products should be reported to MSD Pharmacovigilance within one working day via 0208 1548000. Everyone should be encouraged to report adverse events.

Reporting suspected adverse reactions after authorisation of a medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

PRESCRIBING INFORMATION

The Gardasil-9® UK prescribing information link



Scan the QR code for the Gardasil-9® UK prescribing information and adverse event reporting statement